Studying of Natural Constituents' Treatment of Plantar Warts

Plantar Wart Clinical Trial

Official title:

In-vitro and Randomized Controlled Clinical Studying of Natural Constituents' Anti-HPV Potential for Treatment of Plantar Warts Supported With in Silico Studies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05592041
• Other study ID #: Anti-HPV
• Status: Completed
• Phase: Early Phase 1
• Start date: October 20, 2022
• Est. completion date: January 10, 2023

Study information

• Verified date: May 2024
• Source: Deraya University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Moringa banana nigella and Banna coat extract were prepared and formulated in the form of bi gel for transdermal delivery of these plant extracts. The formulation was prepared and charterized for organoleptic charters, morphology, and penetration efficacy. The optimised formulation was assessed clinically on patients suffering from plantar warts. The clinical study was phase 1 and interventional randomised allocation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: January 10, 2023
• Est. primary completion date: December 18, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 50 Years

Eligibility

Inclusion Criteria:

• Male or female patient aged 18 years or more.

• Clinical evaluation

• Number of warts lower than 10 on the 2 feet and total diameter of warts lower than 10 cm

Exclusion Criteria:

• Patient suspected to be immunocompromised

• Patient aged under 18 years

• Patient refusing to sign the consent

• Pregnant or lactating women

Related Conditions & MeSH terms

• Foot Diseases
• Plantar Wart
• Warts

Intervention

Drug:
• Banaba Leaf Extract
a herbal extract in the form of Bigel

Locations

Country	Name	City	State
Egypt	Soad A. Mohamad	Minya

Sponsors (1)

Lead Sponsor	Collaborator
Deraya University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete clinical remission of the warts	Number of warts (counts)	30 days
Primary	Clinical assessment of warts curement	Diameter of wart in cm	30 days
Secondary	Pain asssesment	pain was assesed by VAS scoring (0) the least to (5) highest	30 days